Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Claseprubart - Dianthus Therapeutics

Next Previous
Drug Profile

Claseprubart - Dianthus Therapeutics

Alternative Names: DNTH 103

Latest Information Update: 15 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dianthus Therapeutics
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1s inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy
  • Phase II Multifocal motor neuropathy; Myasthenia gravis
  • Phase I Autoimmune disorders

Most Recent Events

  • 08 Sep 2025 Dianthus Therapeutics plans end-of-phase II meeting with the USFDA in Myasthenia gravis
  • 08 Sep 2025 Efficacy and adverse events data from a phase II MAGIC trial in Myasthenia gravis released by Dianthus Therapeutics
  • 05 May 2025 Dianthus plans a phase II trial in Myasthenia gravis in Sweden, Netherlands, Argentina, Norway, Macedonia, Czech Republic, Denmark, France, Israel, Italy, USA, Canada, Poland, Serbia (SC) (NCT06282159)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top